Solid Biosciences (SLDB) Revenue & Revenue Breakdown
Solid Biosciences Revenue Highlights
00
Solid Biosciences Revenue by Period
Solid Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $8.09M | -40.57% |
| 2021-12-31 | $13.62M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Solid Biosciences generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Solid Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $3.12M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $4.74M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $8.09M | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $6.17M | 220.47% |
| 2022-03-31 | $1.93M | -38.97% |
| 2021-12-31 | $3.15M | -10.83% |
| 2021-09-30 | $3.54M | -1.59% |
| 2021-06-30 | $3.59M | 7.77% |
| 2021-03-31 | $3.33M | -96.61% |
| 2020-12-31 | $98.32M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
Solid Biosciences generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Solid Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADCT | ADC Therapeutics | $69.28M | $17.40M |
| BCYC | Bicycle Therapeutics | $35.27M | $9.98M |
| AUTL | Autolus Therapeutics | $10.12M | $8.98M |
| FULC | Fulcrum Therapeutics | $2.81M | - |
| INBX | Inhibrx Biosciences | $200.00K | - |
| ALMS | Alumis | - | $17.39M |
| SLDB | Solid Biosciences | - | - |
| NGNE | Neurogene | - | - |
| FDMT | 4D Molecular Therapeutics | - | $14.00K |
| RCKT | Rocket Pharmaceuticals | - | - |
| MBX | MBX Biosciences | - | - |